The two parallel Antibody Mediated Prevention (AMP) prevention efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here we analyzed HIV-1 acquisition in AMP through the Week 104 final study visit. Against viruses considered...
A. deCamp, M. Juraska, Li Li et al.· Science Translational Medici...· 0 citations
The relationship between SARS-CoV-2-specific T cell responses and COVID-19 risk is incompletely understood, particularly after variant-adapted booster receipt. We assessed Spike-specific and Nucleocapsid-specific CD4+ and CD8+ T cell responses, measured by validated 27-color intracellular cytokine staining assay, as co...
Bo Zhang, You-Yi Fong, Chen-Chen Yu et al.· Nature Communications· 0 citations
CD4 + T cell responses are an independent correlate of COVID-19 risk among PWH with pre-existing SARS-CoV-2 immunity, and in people with HIV and hybrid immunity, CD4 + T cell responses at one month post-vaccination correlate inversely with risk of COVID-19 over 6 months.
Sharon Khuzwayo, Bo Zhang, Valentin Voillet et al.· Nature Communications· 1 citation
RTS,S/AS01 (RTS,S) is one of two WHO-recommended malaria vaccines for children in moderate-to-high transmission settings. Yet, no validated immune correlate of protection (CoP) has been established for this vaccine. We selected 16 biomarkers to further assess as candidate CoPs, based largely on their ability to well-pr...
S.-Y. Kim, T. Linnekin, L. Carpp et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.